Emma J. Crosbie
A5004332195- Endometrial and Cervical Cancer Treatments
- Ovarian cancer diagnosis and treatment
- Cervical Cancer and HPV Research
- Genetic factors in colorectal cancer
- Cancer Risks and Factors
- Cancer Genomics and Diagnostics
- Endometriosis Research and Treatment
- Cancer-related molecular mechanisms research
- BRCA gene mutations in cancer
- Colorectal Cancer Screening and Detection
- Estrogen and related hormone effects
- X-ray Diffraction in Crystallography
- Crystallization and Solubility Studies
- Global Cancer Incidence and Screening
- Cancer, Lipids, and Metabolism
- Uterine Myomas and Treatments
- Metabolism, Diabetes, and Cancer
- Genital Health and Disease
- RNA Research and Splicing
- Pelvic floor disorders treatments
- PARP inhibition in cancer therapy
- Cancer Immunotherapy and Biomarkers
- Reproductive System and Pregnancy
- Multiple and Secondary Primary Cancers
- Ectopic Pregnancy Diagnosis and Management
Manchester Academic Health Science Centre
2016-2025
Manchester University NHS Foundation Trust
2017-2025
St Mary's Hospital
2016-2025
University of Manchester
2016-2025
St Mary's Hospital
2017-2025
St. Mary's Hospital
2011-2024
Cancer Research UK Manchester Institute
2013-2024
NIHR Manchester Biomedical Research Centre
2019-2024
National Institute for Health Research
2016-2024
Norwegian Womens Public Health Association
2024
The randomized Adjuvant Chemoradiotherapy Versus Radiotherapy Alone in Women With High-Risk Endometrial Cancer (PORTEC-3) trial investigated the benefit of combined adjuvant chemotherapy and radiotherapy (CTRT) versus alone (RT) for women with high-risk endometrial cancer (EC). Because Genome Atlas defined an EC molecular classification strong prognostic value, we prognosis impact each subgroup using tissue samples from PORTEC-3 participants.Paraffin-embedded tissues 423 consenting patients...
Pathogenic variants affecting MLH1, MSH2, MSH6, and PMS2 cause Lynch syndrome result in different but imprecisely known cancer risks. This study aimed to provide age organ-specific risks according gene gender determine survival after cancer.We conducted an international, multicenter prospective observational using independent test validation cohorts of carriers class 4 or 5 variants. After the were merged providing 6350 participants 51,646 follow-up years.There 1808 prospectively observed...
There are no internationally agreed upon clinical guidelines as to which women with gynecological cancer would benefit from Lynch syndrome screening or how best manage the risk of in syndrome. The Manchester International Consensus Group was convened April 2017 address this unmet need. aim develop clear and comprehensive guidance regarding management sequelae based on existing evidence expert opinion medical professionals patients.
Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as subgroup with poorest prognosis most likely to benefit from adjuvant chemo(radio)therapy. P53abn are POLE wildtype, mismatch repair proficient show abnormal immunohistochemical (IHC) staining for p53. Correct interpretation routinely performed p53 IHC has therefore become paramount importance. We aimed comprehensively investigate patterns their relation...
Risk-assessment of endometrial cancer (EC) is based on clinicopathological factors and molecular subgroup. It unclear whether adding hormone receptor expression, L1CAM expression or CTNNB1 status yields prognostic refinement.Paraffin-embedded tumour samples women with high-risk EC (HR-EC) from the PORTEC-3 trial (n = 424), a Dutch prospective clinical cohort called MST 256), were used. All cases molecularly classified. Expression L1CAM, ER PR analysed by whole-slide immunohistochemistry...
Patients with early-onset colorectal cancer (eoCRC) are managed according to guidelines that not age-specific. A multidisciplinary international group (DIRECt), composed of 69 experts, was convened develop the first evidence-based consensus recommendations for eoCRC.
Lynch syndrome is caused by dominantly inherited germline mutations that predispose individuals to colorectal, endometrial, ovarian, and other cancers through inactivation of the cellular mismatch repair system. syndrome–associated are amenable surveillance strategies may improve survival. The age at which should start disputed.To determine whether mutated gene type mutation influence onset cancers.A retrospective cohort study with and/or ovarian whose medical records were included in...
Obesity is the strongest risk factor for endometrial cancer (EC). To inform targeted screening and prevention strategies, we assessed impact of obesity subsequent bariatric surgery-induced weight loss on morphology molecular pathways implicated in carcinogenesis. Blood tissue were obtained from women with class III-IV (body mass index ≥40 ≥50 kg/m2 , respectively) immediately prior to gastric bypass or sleeve gastrectomy, at two 12 months' follow up. The endometrium underwent pathological...
High-risk endometrial cancer (EC) is an aggressive disease for which new therapeutic options are needed. Aims of this study were to validate the enhanced immune response in highly mutated ECs and explore profiles other EC subgroups. We evaluated infiltration 116 high-risk from TransPORTEC consortium, previously classified into four molecular subtypes: (i) ultramutated POLE exonuclease domain-mutant (POLE-mutant); (ii) hypermutated microsatellite unstable (MSI); (iii) p53-mutant; (iv) no...
Background The serum biomarker cancer antigen 125 (CA125) is widely used as an investigation for possible ovarian in symptomatic women presenting to primary care. However, its diagnostic performance this setting unknown. We evaluated the of CA125 care detection and non-ovarian cancers. Methods findings studied United Kingdom Clinical Practice Research Datalink with a test performed between 1 May 2011–31 December 2014. Ovarian cancers diagnosed year following testing were identified from...
BackgroundEndometrial cancer (EC) is the most common gynaecological in developed nations and its incidence rising. As a direct consequence, more women are dying from EC despite advances care improved survivorship. There lack of research activity funding, as well public awareness about EC. We sought to engage patients, carers healthcare professionals identify important unanswered questions EC.MethodologyThe priority setting methodology was by James Lind Alliance involved four key stages:...
ObjectiveLynch syndrome (LS) is an inherited tumor predisposition condition caused by mutations in the mismatch repair (MMR) genes. Mutation carriers are at increased risk of various malignancies, including ovarian cancer (OC). Relatively little known about pathological features and clinical behavior LS associated OC.MethodsWe analyzed data 1047 proven MMR mutated individuals from a prospectively maintained database large referral center for genomic medicine North West England. Data were...